Clinical Policy: Gemtuzumab Ozogamicin (Mylotarg)
Reference Number: CP.PHAR.358
Effective Date: 10.03.17
Last Review Date: 11.18
Line of Business: Commercial, Medicaid, HIM-Medical Benefit

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Gemtuzumab ozogamicin (Mylotarg™) is a CD33 directed antibody-drug conjugate.

FDA Approved Indication(s)
Mylotarg is indicated for the treatment of:
- Newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults
- Relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Mylotarg is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Acute Myeloid Leukemia (must meet all):
      1. Diagnosis of CD33-positive AML;
      2. Prescribed by or in consultation with an oncologist or hematologist;
      3. Member meets a or b:
         a. Age ≥ 18 years with newly-diagnosed disease;
         b. Age ≥ 2 years with relapsed or refractory disease;
      4. Request meets one of the following (a or b):
         a. Dose does not exceed the FDA approved dose and schedule (see Section V);
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   Approval duration: 12 months (Up to a total of 10 doses)

   B. Acute Promyelocytic Leukemia (off-label) (must meet all):
      1. Diagnosis of acute promyelocytic leukemia;
      2. Prescribed by or in consultation with an oncologist or hematologist;
      3. Age ≥ 2 years;
      4. Request meets one of the following (a or b):
         a. Dose does not exceed the FDA approved dose and schedule (see Section V);
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
CLINICAL POLICY
Gemtuzumab Ozogamicin

Approval duration: 12 months (Up to a total of 10 doses)

C. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Mylotarg for a covered indication and has received this medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. For AML, member has NOT received the maximum treatment cycles recommended as described below (a, b or c):
         a. In combination with daunorubicin and cytarabine for newly diagnosed AML: up to 5 doses;
         b. As single agent for newly diagnosed AML: up to 10 doses;
         c. Relapsed or refractory AML: up to 3 doses;
      4. If request is for a dose increase, request meets one of the following (a or b):
         a. New dose does not exceed the FDA approved dose and schedule (see Section V);
         b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   Approval duration: 12 months (Approve requested number of doses required to complete therapy and not to exceed a total of 10 doses)

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

      Approval duration: Duration of request or 6 months (whichever is less); or

      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   AML: acute myeloid leukemia
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): hypersensitivity
- Boxed warning(s): hepatotoxicity

Appendix D: General Information
- Mylotarg originally received accelerated approval in May 2000 as a stand-alone treatment for older patients with CD33-positive AML who had experienced a relapse. Mylotarg was voluntarily withdrawn from the market after subsequent confirmatory trials failed to verify clinical benefit and demonstrated safety concerns, including a high number of fatal induction adverse events. The recent FDA approval is at a lower dose (previously 9 mg/m²) and different treatment schedule.
- Mylotarg prescribing information includes a black box warning related to hepatotoxicity, including severe or fatal hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, associated with the use of Mylotarg.
- Refer to prescribing information for dose modifications for hematologic and nonhematologic toxicities.
- NCCN treatment guidelines for AML recommend (Category 2A) Mylotarg for acute promyelocytic leukemia in the induction, consolidation, and first relapse setting.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML newly-diagnosed (combination regimen)</td>
<td><strong>Induction:</strong> 3 mg/m² (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine. If a second induction cycle is required, do NOT administer Mylotarg. <strong>Consolidation:</strong> 3 mg/m² on Day 1 (up to one 4.5 mg vial) in combination with daunorubicin and cytarabine for two cycles.</td>
<td>4.5 mg/dose (for one induction and two consolidation cycles)</td>
</tr>
<tr>
<td>AML newly-diagnosed (single-agent regimen)</td>
<td><strong>Induction:</strong> 6 mg/m² on Day 1 and 3 mg/m² on Day 8 <strong>Continuation:</strong> 2 mg/m² on Day 1 every 4 weeks for up to 8 cycles</td>
<td>Induction: 6 mg/m²/dose (for one cycle) Maintenance: 2 mg/m² every 4 weeks for up to 8 doses</td>
</tr>
</tbody>
</table>
Indication | Dosing Regimen | Maximum Dose
---|---|---
AML relapsed or refractory (single-agent regimen) | 3 mg/m² (up to one 4.5 mg vial) on Days 1, 4, and 7 | 4.5 mg/dose (for one cycle)

VI. Product Availability
Single-dose vial for injection: 4.5 mg as a lyophilized cake or powder

VII. References

Reviews, Revisions, and Approvals

| Policy created | 10.03.17 | 11.17 |
| 4Q 2018 annual review: added HIM-Medical; added prescriber requirement; added COC language; for acute promyelocytic leukemia, added age limit and removed requirement for use only for relapse as NCCN compendia include use for induction and consolidation; references reviewed and updated. | 07.18.18 | 11.18 |

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.
This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.